This report provides a brief overview of approaches to manage the pricing of preventive therapies such as novel vaccines, and treatments in times of public health emergencies. Starting with a summary of experience and lessons learned from previous epidemics and the annual flu vaccine, we will then analyze the potential advantages and disadvantages of alternative policy options. Each option takes a different approach toward the role of government and the private market, with pricing being one element in a broader policy platform.
This report is intended as a short introductory overview to inform public and policymaker discussion regarding the best way to harness public and private efforts to achieve rapid, equitable, and affordable treatment for COVID-19 in the US.
